1.
Gut
; 70(Suppl 4):A3-A4, 2021.
Artículo
en Inglés
| ProQuest Central | ID: covidwho-1506204
RESUMEN
OFR-8 Figure 1ConclusionsInfliximab is associated with attenuated immunogenicity to a single-dose of the BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines. Vaccination after SARS-CoV-2 infection, or a second dose of vaccine, led to seroconversion in most patients. Delayed second dosing should be avoided in patients treated with infliximab.